-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Dermatofibrosarcoma Protuberans (DFSP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Dermatofibrosarcoma Protuberans (DFSP) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Dermatofibrosarcoma Protuberans (DFSP) Drug Details: Eribulin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Primitive Neuroectodermal Tumor (PNET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Primitive Neuroectodermal Tumor (PNET) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Primitive Neuroectodermal Tumor (PNET) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Rhabdomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Rhabdomyosarcoma Drug Details: Eribulin mesylate (E-7389, Halaven,Teceris) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Ewing Sarcoma Drug Details: Eribulin mesylate (E-7389,...
-
Sector Analysis
United Kingdom (UK) Baby Food Market Size and Share by Categories, Distribution and Forecast to 2028
United Kingdom (UK) Baby Food Market Report Overview The UK baby food market size reached GBP464.1 million ($574.2 million) in 2022. The market is expected to achieve a CAGR of more than 5% during 2022-2028. UK Baby Food Market Outlook, 2022-2028 (GBP Million) Buy the Full Report for More Insights on the UK Baby Food Market Forecast, Download A Free Report Sample The UK baby food market research report puts together multiple data sources to provide a comprehensive baby food...
-
Product Insights
Ablation Equipment Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Ablation Equipment Pipeline Market Report Overview An Ablation Equipment is a device used to surgically remove a body tissue. The Ablation Equipment pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Territories ·       The US ·       Europe...
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...
-
Company Profile
Peloton Interactive Inc – Company Profile
Peloton Interactive Inc (Peloton Interactive), formerly Peloton Interactive LLC, offers bikes, tread, fitness apparel and accessories. The company's product portfolio comprises internet-connected stationary bikes, treadmills, cycling shoes, dumbbells, resistance bands, and fitness apparel. It also provides connected fitness subscriptions, access to live and on-demand fitness group classes at home that are led by its instructors, and the Peloton Digital app for household users to access its classes. Peloton Interactive sells its products directly to customers through a multi-channel sales platform...
Add to Basket -
Company Profile
Global-e Online Ltd – Company Profile
Global-e Online Ltd (Global-e) provides is a cross-border e-commerce solutions. The company provides a platform for retailers to trade in international markets. It carries out solutions for retailers to sell products beyond the domestic market. Global-e enables retailers to sell over globally with different payment methods. It also include in global-e enterprise, global-e Pro and meta partnership. Global-e end-to-end solutions that combine best-in-class localisation capabilities, big-data best-practice business intelligence models, streamlined international logistics and vast cross-border. The company also operates...
Add to Basket -
Analyst Opinions
Broker Distribution Insight – Which Insurers Lead The Way?
Broker Distribution Insight Report Overview Brokers' goals have slightly changed as the UK economy emerges from the COVID-19 pandemic and heads into a potential recession. The importance of underwriting flexibility to brokers has grown significantly in recent years, with brokers ranking it the most important factor when choosing an insurer. Brokers were increasingly choosing insurers as the best-in-class for relationship managers in 2023, so insurers must make sure they keep excellent ties with brokers. To maximize the benefits of cooperation,...